{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:04:37Z","timestamp":1790813077768,"version":"4.1.0"},"reference-count":30,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T00:00:00Z","timestamp":1437004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Urology"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p> The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone acetate and enzalutamide), chemotherapeutics (docetaxel and cabazitaxel), an autologous vaccine (sipuleucel-T) and a radiopharmaceutical (radium-223). Abiraterone acetate, a prodrug of abiraterone, inhibits the CYP17A enzyme, a critical enzyme in androgen biosynthesis. Abiraterone has regulatory approval in mCRPC in both chemotherapy-na\u00efve patients and in the post-docetaxel setting based on results from two randomized phase III studies. In the COU-AA-302 trial, abiraterone demonstrated significant improvement in the coprimary endpoints of radiographic progression-free survival and overall survival, as well as in a number of secondary endpoints including time until initiation of chemotherapy, time until opiate use for cancer-related pain, prostate-specific antigen progression-free survival and decline in performance status. Abiraterone is well-tolerated, although adverse events associated with this agent include abnormalities in liver function testing and mineralocorticoid-associated adverse events. This review evaluates the use of abiraterone in mCRPC prior to the use of chemotherapy. <\/jats:p>","DOI":"10.1177\/1756287215592288","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T12:03:54Z","timestamp":1437048234000},"page":"194-202","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":35,"title":["Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy"],"prefix":"10.1177","volume":"7","author":[{"given":"Benjamin A.","family":"Gartrell","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 111 E 210 St, Bronx, NY 10467, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de I\u2019Universit\u00e9 de Montr\u00e9al, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,7,16]]},"reference":[{"key":"bibr1-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315815"},{"key":"bibr2-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9749"},{"key":"bibr3-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(94)90131-7"},{"key":"bibr4-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"bibr5-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2014.53"},{"key":"bibr6-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.5013"},{"key":"bibr7-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9259"},{"key":"bibr8-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"bibr9-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.7675"},{"key":"bibr10-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2013.41"},{"key":"bibr11-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.3696"},{"key":"bibr12-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1595"},{"key":"bibr13-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3332"},{"key":"bibr14-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt138"},{"key":"bibr15-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601879"},{"key":"bibr16-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0968"},{"key":"bibr17-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"bibr18-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"bibr19-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.02.056"},{"key":"bibr20-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.03.020"},{"key":"bibr21-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.5086"},{"key":"bibr22-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0815"},{"key":"bibr23-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096"},{"key":"bibr24-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7"},{"key":"bibr25-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"bibr26-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.4777"},{"key":"bibr27-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.037"},{"key":"bibr28-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"bibr29-1756287215592288","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.4578"},{"key":"bibr30-1756287215592288","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21262"}],"container-title":["Therapeutic Advances in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756287215592288","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756287215592288","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756287215592288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T16:37:49Z","timestamp":1740760669000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756287215592288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,16]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1177\/1756287215592288"],"URL":"https:\/\/doi.org\/10.1177\/1756287215592288","relation":{},"ISSN":["1756-2872","1756-2880"],"issn-type":[{"value":"1756-2872","type":"print"},{"value":"1756-2880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,16]]}}}